title: Effects of five-year intensive multifactorial intervention on the serum amyloid A and macroangiopathy in patients with short-duration type 2 diabetes mellitus.
abstract: BACKGROUND
  A five-year follow-up study of intensive multifactorial intervention was undertaken to assess the changes of circulating serum amyloid A (SAA) levels and the incidence of atherosclerosis (AS) in patients with short-duration type 2 diabetes mellitus (T2DM) without macroangiopathy, and whether intensive multifactorial intervention could prevent or at least postpone the occurrence of macroangiopathy.
  
  
  METHODS
  Among 150 patients with short-duration T2DM, 75 were assigned to receive conventional outpatient treatment (conventional group) and the others underwent intensive multifactorial integrated therapy targeting hyperglycemia, hypertension, dyslipidemia and received aspirin simultaneously (intensive group).
  
  
  RESULTS
  Plasma SAA levels were higher in diabetic patients than those in healthy control subjects, and decreased obviously after intensive multifactorial intervention. The levels of SAA were positively correlated with body mass index (BMI), waist hip ratio (WHR), triglyceride (TG), high sensitive C-reactive protein (hs-CRP) and common carotid intima-media thickness (CC-IMT). The standard-reaching rates of glycemia, blood pressure and lipidemia were significantly higher in intensive group than those of conventional group. The incidence of macroangiopathy decreased by 58.96% in intensive group compared with conventional group.
  
  
  CONCLUSIONS
  Intensive multifactorial intervention may significantly reduce the SAA levels and prevent the occurrence of AS in short-duration patients with T2DM. SAA might be one of the risk factors of T2DM combined with AS.
authors: Department of Endocrinology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China.
authors: Jian-ling
authors: JL
authors: Du
authors: Jian-feng
authors: JF
authors: Liu
authors: Li-li
authors: LL
authors: Men
authors: Jun-jie
authors: JJ
authors: Yao
authors: Li-peng
authors: LP
authors: Sun
authors: Guo-hua
authors: GH
authors: Sun
authors: Gui-rong
authors: GR
authors: Song
authors: Yu
authors: Y
authors: Yang
authors: Ran
authors: R
authors: Bai
authors: Qian
authors: Q
authors: Xing
authors: Chang-chen
authors: CC
authors: Li
authors: Chang-kai
authors: CK
authors: Sun
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism*; D003925:Diabetic Angiopathies / Q000209:etiology*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D000685:Serum Amyloid A Protein / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood; D017540:Tunica Media / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D000685:Serum Amyloid A Protein; D014280:Triglycerides; D002097:C-Reactive Protein